Streetwise Reports' Article Archives — Current Month (18)

Biotech Could Launch Trial of Polyp Screening Test in March (01/18/2022)

The start of the C-Scan study would be a major milestone for Check-Cap, noted an H.C. Wainwright & Co. report.


Derm Biopharma Named Top Growth Pick For 2022 (01/18/2022)

Journey Medical should increase 2022 and 2023 revenue by at least 30% such that it could turn a profit in 2024, noted a ROTH Capital Partners report.


This Pharmaceutical Company Has a Brilliant Concept (01/17/2022)

Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs. The company currently has a market cap of US$11.25M, $2M cash in the bank, and several promising late-stage drugs — and it is bound for the NASDAQ. Its closest competitors working on similar illnesses and at similar stages have market caps between $91 and $660 million. Catalysts abound with this genius repurposing company.


Ph1 Trial Results of Dementia Drug Positive (01/12/2022)

Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints, noted a Dawson James Securities report.


Cell Firm Joins With Food Co. to Create Meat Substitute (01/12/2022)

Pluristem Therapeutics and Tnuva will incorporate a new company that will use its own funding and resources to develop cell-based synthetic meat products, noted a Dawson James Securities report.


Vaccine Maker Doses 1st Patient in Phase 1b Parkinson's Trial (01/12/2022)

Shares of new class synthetic vaccine developer Vaxxinity Inc. traded 23% higher after the company reported it has dosed the first patient in its Phase 1b UB-312 Parkinson's disease study.


Biotech Co. Partners With Life Sciences Firms (01/11/2022)

2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed, noted a Wedbush report.


HealthCare Solutions Co. Gains 8 Million New Members in 2021 (01/11/2022)

Accolade Inc. shares rose 27% after the company reported Q3/22 financial results that included a 117% increase in YoY revenue. The firm highlighted that in calendar year 2021, its membership increased four-fold from 2 million to 10 million.


2022 to Be Catalyst Rich for Biopharma (01/10/2022)

The potential stock-moving events for Infinity Pharmaceuticals this year include the launch of two clinical trials and readouts from four studies, noted an H.C. Wainwright & Co. report.


Enrollment Done for COVID-19 Drug Trial (01/10/2022)

Part 2 of First Wave BioPharma's RESERVOIR trial of niclosamide to remove the SARS-CoV-2 virus from the GI tract is underway, noted a ROTH Capital Partners report.


Co.'s samRNA Vaccines Protect Better Against COVID Variants (01/07/2022)

Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio.


AI Driven Drug Firm Partners With Merck (01/07/2022)

Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creation™ platform and Bionic Protein™ technologies.


Co. Partners to Test New Cancer Vaccines (01/06/2022)

Genocea Biosciences Inc. is teaming up with Janssen Biotech to explore the immunogenicity of neoantigens and the role and impact of Inhibigens™ in potential vaccine therapies for cancer. H.C. Wainwright & Co. advised that it currently has a "Buy" rating on Genocea.


Medical Co. Strikes $3B Deal to Buy Digital Care Firm (01/06/2022)

Shares of Vocera Communications Inc. traded nearly 27% higher after the company reported it entered into a definitive agreement to be acquired by Stryker Corp. for $79.25 per share in cash.


Chen Lin's Top 6 Investment Ideas (01/05/2022)

In a recent interview with Streetwise Reports, family assets manager and contributing writer, Chen Lin, shared the six (mostly mid-cap) companies that are his top investment picks for 2022.


New Muscular Dystrophy Drug Shows Promise (01/05/2022)

Edgewise Therapeutics shares traded 24% higher after the company reported its EDG-5506 significantly lowered muscle damage biomarkers in adults after just two weeks of dosing in its Becker muscular dystrophy trial.


Co. Plans to Make 100M Rapid COVID Tests Monthly (01/05/2022)

Biopharmaceutical firm Sorrento Therapeutics Inc. plans to mobilize a fully automated assembly line in San Diego, Calif., capable of producing 6 million rapid antigen detection COVISTIX testing units per month starting in Q1/22.


Lead Cancer Drug Gets Fast Tracked (01/03/2022)

Shares of Genprex Inc. traded 165% higher after the company reported the U.S. FDA has awarded Fast Track Designation for its REQORSA™ Immunogene Therapy for use in combination with Merck & Co.'s Keytruda® for non-small cell lung cancer treatment.


More Archives


2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2018Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2017Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes